Protective Efficacy of the Calicivirus Valency of the Leucofeligen Vaccine against a Virulent Heterologous Challenge in Kittens

Cynthia Lesbros, Virginie Martin, Wojciech Najbar, Annaele Sanquer, David McGahie, Hyone-Myong Eun, and Sylvie Gueguen

1 R&D Department, Virbac, 13ème rue, LID, BP 27, 06511 Carros Cedex, France
2 Medical Department, Virbac, 13ème rue, LID, BP 27, 06511 Carros Cedex, France

Correspondence should be addressed to David McGahie; david.mcgahie@virbac.com

Received 19 February 2013; Revised 6 May 2013; Accepted 4 June 2013

1. Introduction

Feline calicivirus (FCV) is a common feline pathogen with a potential for antigenic diversity. This study aimed to evaluate and characterize the protective efficacy of the FCV-F9 valency of a tetravalent vaccine, Leucofeligen, against challenge with an unrelated strain. Ten 9-week-old kittens were vaccinated while 10 remained as unvaccinated controls. The vaccinated cats received Leucofeligen twice subcutaneously with a 3-week interval. Four weeks after the second vaccination, all cats were challenged with virulent heterologous FCV and followed up for 21 days, monitoring their general condition, clinical signs, and immunological responses. During the vaccination phase, rectal temperatures and body weights were indistinguishable between the two groups. Only vaccinated cats showed FCV-specific seroconversion (both total and neutralizing antibodies). In the first week after challenge, the vaccinated cats had an 82.6% reduction in median clinical score compared to controls. Leucofeligen was thus shown to provide a significant clinical protection to kittens challenged with heterologous virulent FCV. This protection was similar whether the cats had neutralizing antibody or not, indicating a key role for cellular immunity in the overall protection. This also suggests that previously reported seroneutralisation studies may underestimate the level of cross-protection against field strains obtained with this modified live FCV-F9 vaccine.
accordance with the recommendations issued in the European Pharmacopoeia [6].

2.1. Animals and Study Protocols. Twenty specific-pathogen-free (SPF) European kittens, 9 weeks old, were randomly assigned to 2 groups: control (unvaccinated, hereafter designated group C) and vaccinated (hereafter designated group V). Cats were acclimatized for 6 days to the animal housing conditions (12 h light/dark cycle, 18 ± 3°C, 55 ± 10% humidity, with free access to water). Each group was housed in a separate airspace in the animal housing facility.

Group V cats were vaccinated twice at a 3-week interval (day 0 and day 21) by subcutaneous injection (1 mL) according to the recommendations of the manufacturer. In order to better assess the local tolerance of the injections, the first injection was given half way between the shoulder and hip on the right side, and left side was used for the second injection. Group C cats did not receive any injections.

Four weeks after the second vaccination, on day 49, equivalent to postchallenge time 0 (= pct0), all cats were challenged with a virulent heterologous strain of calicivirus (FCV-255). Cats were first anesthetized and then inoculated intranasally with 10^{3.2} TCID_{50}/cat of FCV-255 suspension using a volume of 0.25 mL/nostril.

2.2. Test Vaccine. Leucofeligen was granted a pan-European marketing authorization (centralised procedure) in 2009. It is presented as a freeze-dried fraction containing the live attenuated viruses, that is, FCV (F9), FHV-1 (F2), and FPV (LR72), and a liquid fraction containing the recombinant FeLV-envelope antigen p45 (derived from the gp70 of FeLV) with aluminium hydroxide and QA-21 adjuvants. The calicivirus neutralizing antibody (NAb) titres. The serological assessments involved assaying IgG anticalicivirus antibody (Ab) and anticalicivirus neutralizing antibody (NAb) titres.

2.4. Serological Assessments. The serological assessments of each serum were performed daily (adding the scores recorded each day for each parameter in each cat) was used to assess differences in the severity of the clinical picture, and the cumulative score (taking the highest recorded score for each parameter in each cat) was used to evaluate the impact of the duration of each sign. For both of these comparisons, scores for rectal temperature, ulceration, nasal discharge, ocular discharge, and weight loss were included. As weight loss represents a single score on day pct7 (representing the loss over the previous week) it has the same impact on both maximum and cumulative scores.

### Table 1: Scoring system for the parameters concerning general health conditions and clinical signs.

| Symptoms               | Description | Notation |
|------------------------|-------------|----------|
| Rectal temperature (°C) | ≤ 39.5      | 1        |
|                         | ≥ 39.5      | 1        |
|                         | ≤ 37.0      | 2        |
| Body weight*            | Gain or loss of <3% | 0        |
|                         | Loss of ≥3% | 2        |
| Ulcers (oral and/or nasal) | Absence       | 0        |
|                         | Small and few | 1        |
|                         | Large or numerous | 3        |
| Nasal discharge         | Absence     | 0        |
|                         | Slight      | 1        |
|                         | Copious     | 2        |
| Ocular discharge        | Absence     | 0        |
|                         | Presence    | 1        |

*Weight loss (%) = 100 × ([pct7] − [pct0])/[pct0].

Blood samples were collected from the animals in uncoated tubes for serological assessment on days 0, 21, 35, 49 (= pct0), 56 (= pct7), 63 (= pct14), and 70 (= pct21).

2.4.1. IgG Ab. Titres of IgG against calicivirus were assessed using an immunofluorescent antibody assay. Briefly, 50 μL of two-fold dilutions of each serum (from 1/64 to 1/8192) was added to a 96-well plate containing acetone-fixed CRFK cells infected with FCV-F9. 50 μL of a positive serum and 50 μL of a negative serum were diluted in the same way and used as controls. They were incubated for 1 hour at 37°C and revealed with a fluorescein-conjugated antifeline IgG antibody and a solution of Evans Blue. The positivity threshold was 1/128.

2.4.2. Neutralising Ab. Titres of NAb were determined to the homologous FCV-F9. Briefly, 50 μL of each serum was diluted with L15/McCoy’s medium to provide 6 2-fold dilution steps between 1/8 and 1/256. 200 μL per dilution was incubated for 1 hour with 200 μL of FCV-F9 suspension at a concentration of approximately 100 TCID_{50} to allow viral neutralisation. 50 μL of each mixture was then added to 6 plates of a 96-well plate containing 70% confluent CRFK cells. After 6 days of incubation, the characteristic cytopathic effect was assessed. The titre was determined by the Spearman and Karber method [7] and considered as negative when inferior to 0.9 which was the detection threshold.

2.5. Statistical Tests. All statistical analyses were performed using the S-PLUS 6.2 software package (Insightful, Paris). For the comparison of rectal temperatures, body weights, and clinical scores between group C and group V, Student’s t-tests, one-sided Wilcoxon rank sum tests, and/or the one-sided Dunnett method were applied. A P value <0.05 was considered as significant.
2.6. Ethical Approval. This work was performed under the supervision of the Ethical Committee of Virbac, and in accordance with the requirements of the official European Pharmacopoeia [6].

3. Results

3.1. Vaccinal Phase

3.1.1. General Health Parameters. During the vaccination phase (day 0 to 49), all cats remained in normal health with a steady increase in their body weights and with normal body (rectal) temperatures. No abnormal general or local reactions were noted in relation to the vaccinations administered.

3.1.2. Clinical Signs. No cat in either group displayed any clinical signs during the vaccination phase.

3.1.3. Immune Responses. The time course of the Ab responses induced by FCV-F9 vaccination (day 0–49, vaccination phase) is shown in Figure 1 (anti-FCV-NAb) and Figure 2 (anti-FCV-IgG antibodies). Regarding anti-FCV-NAb responses (Figure 1), all vaccinated cats seroconverted by day 35. On day 49 (pct = 0), however, the 5 cats with titres less than or equal to $10^{-1.3}$ had returned to be NAb negative. All control cats remained strictly NAb negative in the same period.

In contrast to the NAb responses, anti-FCV-IgG responses were elicited in a uniform and strong manner in all vaccinated cats by day 35 and they remained high on day 49 (Figure 2).

3.2. Postchallenge Phase

3.2.1. General Health Parameters. At the start of the challenge phase (pct0), there was no difference in the body weights of the two groups ($P = 1.00$). In the first week of the postchallenge phase (pct0 to pct7), the body weights of 9 out of 10 of the group C cats decreased (mean weight loss of 6.75%), in contrast to the group V cats which maintained a normal pattern of weight gain (mean weight gain 4.66%) during this period (Figure 3). The difference in percentage of weight gain or loss during the first week after challenge between the groups was highly significant ($P < 0.0001$).

During the same time period, hyperthermia ($>39.4^\circ C$) was observed for every cat in group C on at least 2 of the days,
with 4 of the 10 cats presenting peaks of at least 40°C and one of them sustaining a rectal temperature of >40°C for 4 days. In contrast, in group V transient peaks, lasting no more than 1 day, were observed in 7 of the 10 cats. 3 of those were only 39.5°C, and none of the group V cats reached 40°C. Mean rectal temperatures were significantly different between the two groups on days 3 to 5 after challenge (P between 0.0002 and 0.0137) and are displayed in Figure 4.

3.2.2. Clinical Signs and Comparison of Scores. During the first week after FCV challenge (pct0 to pct7) a significant difference was observed between the groups regarding the development of clinical signs.

Nine of the 10 group C cats developed oral and/or nasal ulcers: 4 cats had the maximum score of 3 (corresponding to large and/or numerous ulcers—see Table 1 for details) with one maintaining this maximum score for 12 days, and the other 5 cats had a score of 1 (corresponding to small ulcers, few in number). In contrast, only one cat in group V developed oral ulceration with a score of 3 (for only 4 days), while 4 others developed mild ulceration with a score of 1. Ocular discharge was observed in one group C cat but never in the vaccinated cats. Nasal discharge was far more common, affecting 5 group C cats, but again no group V cats demonstrated nasal discharge at any time.

In general, group V cats developed substantially reduced clinical signs and for a substantially shorter duration compared with the control cats (Figure 5). The maximum clinical scores during the first week after challenge were significantly reduced in group V compared to group C: reduction in the median was 80% (P = 0.0002). The reduction in the median of the cumulative clinical scores was also significant at 82.6% (P = 0.0004) (Table 2).

After the first week following challenge, and entirely as expected, most cats improved rapidly. However, cumulative scores for ulceration remained significantly different between pct8 and pct21 (P = 0.014) with a 95.0% reduction in the vaccinated group during this period.

3.2.3. Immune Responses. Following the heterologous FCV-challenge on day 49 (= pct0), the mean homologous NAb titres (Figure 1) rose substantially (6.6-fold) in the vaccinated group. One cat in this group, which had a nondetectable NAb titre at the time of challenge, had a delayed and only moderate appearance of the NAb titre which could be detected only after pct14. However, the only sign noted for this cat throughout the entire challenge period was a very slight rise in rectal temperature of 0.1°C above the threshold on one single occasion only. The other 4 cats with nondetectable NAb titres at the time of challenge had reseroconverted on pct7. Control cats remained NAb negative throughout the challenge period except for one cat that elicited a detectable level of NAb on pct14 and pct21.

The stimulation of anti-FCV-IgG responses (Figure 2) in the group V cats was rapid and substantial, with a 5-fold increase in mean titres during the first week after the challenge. The anti-FCV-IgG response to challenge in the group C cats began later but was then rapid and intense. From pct14, all 10 cats developed substantial titres of anti-FCV-IgG in a very uniform fashion, in contrast with the virtual absence of NAb. By pct21, the anti-FCV-IgG titres reached levels similar to or even higher than those of the vaccinated cats.

4. Discussion

Due to the variable nature of FCV, the ability to cross-protect against unrelated strains is a key requirement for an
Table 2: Cumulative clinical scores (CS) using the scoring system as defined in Table 1 for the individual cats during the first week after challenge.

| Cat ID group V | Cumulative CS Week 1 (pct0 to pct7) | NAb at challenge | Cat ID group C | Cumulative CS Week 1 (pct0 to pct7) | NAb at challenge |
|---------------|--------------------------------------|------------------|---------------|--------------------------------------|------------------|
| 1             | 12                                   | (-)              | 1             | 10                                   | (-)              |
| 2             | 3                                    | (-)              | 2             | 11                                   | (-)              |
| 3             | 0                                    | (+)              | 3             | 13                                   | (-)              |
| 4             | 1                                    | (+)              | 4             | 8                                    | (-)              |
| 5             | 1                                    | (-)              | 5             | 8                                    | (-)              |
| 6             | 4                                    | (-)              | 6             | 29                                   | (-)              |
| 7             | 1                                    | (+)              | 7             | 12                                   | (-)              |
| 8             | 4                                    | (+)              | 8             | 7                                    | (-)              |
| 9             | 6                                    | (+)              | 9             | 16                                   | (-)              |
| 10            | 1                                    | (-)              | 10            | 18                                   | (-)              |
| Median        | 2.0                                  |                  | Median        | 11.5                                 |                  |
| Q25%;Q75%     | 1.0; 4.0                             |                  | Q25%;Q75%     | 8.0; 16.0                            |                  |
| Mean [95% CI] | 3.3 [0.7; 5.9]                       |                  | Mean [95% CI] | 13.2 [8.5; 17.9]                     |                  |

The choice of FCV-255 as a heterologous challenge strain was legitimate due to the dissimilarity of the two virus strains. It seems that the maximum dissimilarity detected within the calicivirus pool is in the order of 30% [5], and one study demonstrated that FCV-255 and F9 have only 70% homology within region E of the capsid protein, which is a similar level of relatedness to that seen with other highly diverse strains including some of the highly virulent strains examined in that study [9]. In one seroneutralisation study performed with sera raised to FCV-255 and F9, it was clear that amongst the field strains neutralised by the highest antibody dilution titres of one of the sera there was rarely a corresponding high titre for the other serum [10].

The level of clinical protection achieved in this study was very encouraging. Current guidelines [11] suggest that in high-risk environments, such as rescue shelters, we can reasonably expect vaccines for feline calicivirus to provide around 60 to 70% protection due to the higher levels of exposure. In this study exposure was guaranteed at high doses by the direct intranasal administration of the pathogenic virus. Therefore achieving an 82.6% reduction in median scores over the first week after challenge in such circumstances is an excellent result. As the disease is self-limiting in immunocompetent cats, and most cats begin to heal spontaneously in around 7 to 10 days after the onset of the disease, the first week after challenge is the most appropriate period to assess the benefit obtained as a result of vaccination. The signs which are most visible for the pet owner (nasal discharge, ocular discharge, and weight loss) were completely prevented during this time. Likewise severe fever likely to result in noticeable lethargy and malaise was also completely prevented. In this context, it can be noted that, in the monograph for FHV, severe hyperthermia (40°C or higher) is given a higher score, allowing the severity of this sign to be reflected in the final scores [12]. We remained within the FCV monograph for the scoring used in this study, but had the modified score used in the recent FHV monograph been used, the difference between groups would have been even greater due to the fact that the vaccine completely prevented severe hyperthermia.

Ulcers are noticeable to the owner only when widespread and severe. Therefore the reduction in both the duration and the severity of the ulceration also means that it is unlikely that an owner would be aware of these ulcers in a vaccinated cat in the great majority of cases. Complete prevention of ulceration is not expected in such a study with direct administration of high doses of pathogenic virus. Indeed we can assume that the levels of mucosal IgA required to block such doses of virus are unlikely to be achievable, meaning that some cytopathic effect is inevitable. Nevertheless, a reduction in the severity and duration of ulceration and fever is probably the two parameters which most benefit the welfare of the animal, one of the main reasons to use FCV vaccines.

Following the serological responses in addition to the clinical responses was also very interesting in this study. IgG antibodies levels rose to high titres during the challenge phase in all cats in this study, regardless of the severity of the clinical signs, and therefore appear to be simply a marker of exposure to the virus and do not indicate useful information about the level of protection achieved.
During the vaccination phase (day 0–49) of the present study, the titres of anti-FCV-NAb produced by the vaccinated cats were neither high nor long lasting. This is very much in line with previous published work, where studies based on seroneutralisation required use of altered and intense protocols of exposure to the vaccine strains to induce sufficiently high titres to permit cross-neutralisation assays to be performed [9, 10, 13–15]. This raises the possibility that some of the neutralising responses in these studies could also be due to other possibly nonspecific, immune mechanisms not seen in normally vaccinated cats [10].

At the time of the heterologous challenge, cats in our study with detectable levels of NAb were protected against severe disease. However, by contrast, half the vaccinated cats had no detectable NAb, and the lack of NAb was not correlated with susceptibility to the infection.

As a result, we can conclude that high NAb titres appear to function as a marker that an active immune response has been produced but are probably not the key protective agent against this virus. The lack of NAb titres in healed (and presumably therefore immune) control cats strongly supports this conclusion.

Such a result is perhaps not entirely surprising. Indeed in terms of antibody protection, circulating antibody has a minimal benefit to offer in terms of protection against a mucosal virus, where perhaps levels of IgA mucosal antibody would be more interesting if it was possible to assay these accurately. More importantly, when using modified live vaccines, it is widely accepted that cell-mediated immunity is likely to be a major factor in the protection induced by the vaccine [16].

In a study focussed on a bivalent inactivated vaccine [9], the authors found that there was no correlation between neutralising antibody titres and clinical protection, although high antibody titres were predictive of clinical protection. However, when a blocking ELISA assay was used, they found that, in cases where there were significant titres to both of the inactivated FCV strains present in the vaccine, there was an 89% predictive value of a reduction in the clinical score of at least 50%. Use of an inactivated vaccine is less likely to induce strong cell-mediated responses. Taken together, our results and those of Poulet et al. [9] may suggest that although antibody levels could be predictive of cross-protection when inactivated vaccines are used, they greatly underestimate cross-protection when modified live F9 vaccines are used, probably due to a stronger role of the cell-mediated immune response.

This finding on the relevance of NAb titres also confirms the need to perform confirmatory challenge studies in order to be able to draw useful conclusions on the efficacy of an FCV vaccine. It would also be interesting to look further at specific cell-mediated immunity parameters in future studies.

5. Conclusion

Our study demonstrated that the combination vaccine, Leucofeligen, could provide a protective efficacy (reduction of clinical score) of 82.6% during the first week after challenge in vaccinated kittens challenged with virulent heterologous FCV. The signs most visible for the pet owner (nasal discharge, ocular discharge, and weight loss) were completely prevented during this time, as was severe fever likely to result in noticeable lethargy or malaise. High titres of neutralising antibody seem to indicate protection, but the absence of NAb does not indicate susceptibility, indicating a role for cell-mediated immunity with this vaccine. It therefore appears that, when modified live F9 vaccines are used, in vitro seroneutralisation studies are likely to underestimate the level of cross-protection that may be achieved against field strains in vivo.

Conflict of Interests

The paper relates to the performance of a vaccine which is manufactured by Virbac. All the authors of this paper were employed by Virbac, which also funded the study.

References

[1] A. D. Radford, K. P. Coyne, S. Dawson, C. J. Porter, and R. M. Gaskell, "Feline calicivirus," Veterinary Research, vol. 38, no. 2, pp. 319–335, 2007.
[2] S. Rong, D. Slade, K. Floyd-Hawkins, and D. Wheeler, "Characterization of a highly virulent feline calicivirus and attenuation of this virus," Virus Research, vol. 122, no. 1-2, pp. 95–108, 2006.
[3] A. D. Radford, D. Addie, S. Belak et al., "Feline calicivirus infection ABCD guidelines on prevention and management," Journal of Feline Medicine and Surgery, vol. 11, no. 7, pp. 556–564, 2009.
[4] P. A. Pesavento, K. O. Chang, and J. S. L. Parker, "Molecular virology of feline calicivirus," Veterinary Clinics of North America, vol. 38, no. 4, pp. 775–786, 2008.
[5] K. P. Coyne, R. M. Christley, O. G. Pybus et al., "Large-scale spatial and temporal genetic diversity of feline calicivirus," Journal of Virology, vol. 86, no. 20, pp. 11356–11367, 2012.
[6] "Feline calicivirus vaccine (live), freeze-dried," European Pharmacopoeia Monograph 1102.
[7] R. J. Lorenz and K. Bögel, "Laboratory techniques in rabies: methods of calculation," Monograph Series of the World Health Organization, no. 23, pp. 321–335, 1973.
[8] S. Gueguen, V. Martin, L. Bonnet, D. Saunier, P. Mähl, and A. Aubert, "Safety and efficacy of a recombinant FeLV vaccine combined with a live feline rhinotracheitis, caliciviruses and panleucopenia vaccine," Veterinary Record, vol. 146, no. 13, pp. 380–381, 2000.
[9] H. Poulet, D. Jas, C. Lemeter, C. Coupiер, and S. Brunet, "Efficacy of a bivalent inactivated non-adjuvanted feline calicivirus vaccine: relation between in vitro cross-neutralization and heterologous protection in vivo," Vaccine, vol. 26, no. 29–30, pp. 3647–3654, 2008.
[10] C. J. Porter, A. D. Radford, R. M. Gaskell et al., "Comparison of the ability of feline calicivirus (FCV) vaccines to neutralise a panel of current UK FCV isolates," Journal of Feline Medicine and Surgery, vol. 10, no. 1, pp. 32–40, 2008.
[11] M. J. Day, M. C. Horzinek, and R. D. Schultz, "WSAVA guidelines for the vaccination of dogs and cats," Journal of Small Animal Practice, vol. 51, no. 6, pp. 1–32, 2010.
[12] "Feline viral rhinotracheitis vaccine (live), freeze-dried," European Pharmacopoeia Monograph 1206.
[13] D. Addie, H. Poulet, M. C. Golder et al., "Ability of antibodies to two new caliciviral vaccine strains to neutralise feline calicivirus
isolates from the UK,” *Veterinary Record*, vol. 163, no. 12, pp. 355–357, 2008.

[14] S. Dawson, F. McArdle, M. Bennett et al., “Typing of feline calicivirus isolates from different clinical groups by virus neutralisation tests,” *Veterinary Record*, vol. 133, no. 1, pp. 13–17, 1993.

[15] A. Lauritzen, O. Jarrett, and M. Sabara, “Serological analysis of feline calicivirus isolates from the United States and United Kingdom,” *Veterinary Microbiology*, vol. 56, no. 1-2, pp. 55–63, 1997.

[16] C. E. Greene and R. D. Schultz, “Immunoprophylaxis,” in *Infectious Diseases of the Dog and Cat*, C. E. Greene, Ed., chapter 100, pp. 1069–1119, WB Saunders, Philadelphia, Pa, USA, 3rd edition, 2006.